Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2018

Publisher Name :
Date: 10-Jul-2018
No. of pages: 41

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2018

Summary

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Metabotropic glutamate receptor 4 is a protein encoded by the GRM4 gene. It is a G-protein coupled receptor for glutamate. Glutamate binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates the activity of down-stream effectors. Signaling inhibits adenylate cyclase activity.

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Central Nervous System and Immunology which include indications Parkinson's Disease, Multiple Sclerosis, Opium (Opioid) Addiction, Anxiety Disorders, Autoimmune Disorders, Depression, Dyskinesia, Infantile Spasm (West Syndrome), Obsessive-Compulsive Disorder, Psychosis, Status Epilepticus and Substance (Drug) Abuse.

The latest report Metabotropic Glutamate Receptor 4 - Pipeline Review, H2 2018, outlays comprehensive information on the Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)

- The report reviews Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved in Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics and enlists all their major and minor projects

- The report assesses Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news and deals related to Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Pipeline Review, H2 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Overview
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Companies Involved in Therapeutics Development
Addex Therapeutics Ltd
Domain Therapeutics SA
H. Lundbeck AS
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Drug Profiles
ADX-88178 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
foliglurax - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LSP-29166 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGluR4 for Parkinson's Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Agonize mGLUR4 for Parkinson's Disease, Multiple Sclerosis and Autoimmune Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VU-0418506 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Dormant Products
Metabotropic Glutamate Receptor 4 (GPRC1D or MGLUR4 or GRM4) - Product Development Milestones
Featured News & Press Releases
Mar 20, 2018: Domain Therapeutics to receive up to $125 million for assignment of its intellectual property covering the Foliglurax mGluR4 PAM series discovered by the French biotech
Jul 10, 2017: Parkinson's disease: Prexton announces initiation of phase II clinical testing
Oct 11, 2016: Addex Initiates New Study in Collaboration with US National Institute of Drug Abuse with ADX88178 in Non-Human Primate Model of Cocaine Addiction
Sep 19, 2016: Parkinson's disease: Prexton Therapeutics completes phase 1 clinical trial
Jun 13, 2016: Addex mGluR4 Program Demonstrates Potential in Preclinical Models of Neurodegenerative and Psychiatric Diseases
Mar 07, 2016: Parkinson's disease: Prexton Therapeutics starts phase 1 clinical trial
Dec 09, 2015: Addex Scientists Publish New Data Supporting the Potential of mGlu4 Receptor Positive Allosteric Modulators in Multiple Sclerosis
Nov 23, 2015: Addex and CHUV-UNIL Collaborators Awarded Swiss Grant to Advance Addex mGluR4 Allosteric Modulator for Neurodegenerative and Psychiatric Diseases
Oct 02, 2012: Addex Therapeutics And Collaborators Receive CHF700,000 Grant To Develop Allosteric Modulators For Neurodegenerative And Psychiatric Diseases
Sep 24, 2012: Addex Therapeutics's mGluR4 Allosteric Modulator Found To Be Effective In Multiple Sclerosis Model
Jul 16, 2012: Addex Announces Publication Of Positive Data On Efficacy Of New Drug To Treat Parkinson's Disease In Journal Of Pharmacology And Experimental Therapeutics
Jul 10, 2009: Addex In Collaboration With Merck & Co., Inc. Achieves Second Milestone In Parkinson´s Disease
Feb 25, 2008: Addex In Collaboration With Merck & Co., Inc. Achieves First Milestone In Parkinson's Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Indication, H2 2018
Number of Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018
Number of Products under Investigation by Universities/Institutes, H2 2018
Products under Investigation by Universities/Institutes, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Pipeline by Addex Therapeutics Ltd, H2 2018
Pipeline by Domain Therapeutics SA, H2 2018
Pipeline by H. Lundbeck AS, H2 2018
Dormant Projects, H2 2018

List of Figures
Number of Products under Development by Stage of Development, H2 2018
Number of Products under Development by Therapy Areas, H2 2018
Number of Products under Development by Top 10 Indications, H2 2018
Number of Products by Mechanism of Actions, H2 2018
Number of Products by Stage and Mechanism of Actions, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
  • Global Post Herpetic Neuralgia Drugs Market Growth 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 136
    Post herpetic neuralgia is a painful condition that can occur after having shingles, a complication of chicken pox. The goal of therapy for postherpetic neuralgia is to reduce morbidity through the use of tricyclic antidepressants, anticonvulsants, anesthetics, analgesics, corticosteroids and antiviral agents. According to this study, over the next five years the Post Herpetic Neuralgia Drugs market will register a xx% CAGR in terms of revenue, the global market size will reach US......
  • Global Medicinal Cannabis Market Growth 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 159
    Medicinal cannabis is cannabis and cannabinoids that are prescribed by physicians for their patients. Medicinal cannabis is moderate that it helps in chronic pain and muscle spasms. According to this study, over the next five years the Medicinal Cannabis market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key com......
  • Global Industrial Hemp in Medical Market Growth 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 159
    Industrial hemp is varieties of Cannabis sativa that have a tetrahydrocannabinol (THC) content generally below 0.35 percent. According to this study, over the next five years the Industrial Hemp in Medical market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Industrial Hemp in Medical business, sh......
  • Global Liver Health Supplements Market Growth (Status and Outlook) 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 131
    Liver is the largest internal organ in the body and it works as a garbage collector. Liver health and its functionality is important for healthily body function. According to this study, over the next five years the Liver Health Supplements market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, this report presents the global revenue market share of key companies in Liver Health Sup......
  • Global Antiallergic Non-Drug Supplements Market Growth 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 137
    Antiallergic Non-Drug Supplements include nutritional supplements and oil etc, that can be further divided into Capsules, Tablets and Liquids. Allergic patients could be alleviate allergic symptoms through taking antiallergic non-drug supplements. According to this study, over the next five years the Antiallergic Non-Drug Supplements market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In partic......
  • Global Eye Drop Bottle Squeezer Market Growth 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 132
    Patients find difficulty in properly installing drops into eyes due to the result of the inability of grip, unsteady hands, and blink reaction of eyes. Eye Drop Bottle Squeezers are helping to instill drops in the eyes properly. Eye Drop Bottle Squeezers allow more accurate eye drop placement and make eye drops administration easier to control dosage. Eye Drop Bottle Squeezers overcome the difficulty in squeezing the bottle to deliver the eye drops, the complexity of design and amount of right d......
  • Global Eye Drop Dispenser Market Growth 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 135
    Patients find difficulty in properly installing drops into eyes due to the result of the inability of grip, unsteady hands, and blink reaction of eyes. Eye drop dispenser devices are helping to instill drops in the eyes properly. Eye drop dispenser devices allow more accurate eye drop placement and make eye drops administration easier to control dosage. Eye drop dispenser devices overcome the difficulty in squeezing the bottle to deliver the eye drops, the complexity of design and amount of righ......
  • Global Antifibrotic Drugs Market Growth 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 134
    Dermal fibrosis is a fundamental feature of fatty skin sclerosis and is associated with increased levels of the cytokine transforming growth factor-ß. This growth factor may derived from activated leukocytes, recruits macrophages and fibroblasts into the tissue and leads to the production of extracellular matrix proteins By dermal fibroblasts. Anti-Fibrotic Drug as treatment of cutaneous fibrosis that stops the action of TGF-ß, reducing the amount of fibrosis. According to this st......
  • Global Fibrinogen Testing Reagents Market Growth 2019-2024
    Published: 18-Apr-2019        Price: US 3660 Onwards        Pages: 164
    Hypofibrinogenemia is generally asymptomatic, but afibrinogenemia and dysfibrinogenemia may lead to bleeding or thrombosis. Fibrinogen Testing Reagent is an in-vitro immunoturbidimetric test for quantitative determination of fibrinogen in plasma. According to this study, over the next five years the Fibrinogen Testing Reagents market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2024, from US$ xx million in 2019. In particular, t......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs